C12N2795/10021

COMPOSITION OF MATTER: ENGINEERING OF ESCHERICHIA COLI PHAGE K1E
20190330599 · 2019-10-31 ·

The present disclosure provides compositions including recombinant K1E bacteriophages, methods for making the same, and uses thereof. The recombinant K1E bacteriophages disclosed herein are useful for the identification and/or antibiotic susceptibility profiling of specific bacterial strains/species present in a sample.

RECOMBINANT B11 BACTERIOPHAGES AND USES THEREOF

The present disclosure provides compositions including recombinant B 11 bacteriophages, methods for making the same, and uses thereof. The recombinant B 11 bacteriophages disclosed herein are useful for the identification and/or antibiotic susceptibility profiling of specific bacterial strains/species present in a sample.

SYNTHETIC PHAGE WITH RECOMBINANT TAIL-SPIKE PROTEINS AND RELATED METHODS

Described are compositions, methods, systems, and kits related to related to synthetic phages with a customized host range. Customized host range of the synthetic phage is imparted on the synthetic phage by one or more recombinant tail-spike proteins. For example, a recombinant tail-spike protein may include a combination of the N-terminal region and the C-terminal region is engineered in a laboratory.

Recombinant B11 bacteriophages and uses thereof

The present disclosure provides compositions including recombinant B11 bacteriophages, methods for making the same, and uses thereof. The recombinant B11 bacteriophages disclosed herein are useful for the identification and/or antibiotic susceptibility profiling of specific bacterial strains/species present in a sample.

BACTERICIDE COMPOSITION BASED ON A MIXTURE OF BACTERIOPHAGES FOR THE CONTROL OF BLACK PLAGUE IN PLANTS OR PARTS THEREOF, PREFERABLY THE WALNUT, CAUSED BY XANTHOMONAS ARBORICOLA PV. JUGLANDIS; PREPARATION METHOD AND APPLICATION
20190116799 · 2019-04-25 ·

The invention relates to a bactericide composition based on bacteriophages for the control of black plague in plants or parts thereof, preferably walnuts, a preparation method and application. The invention provides methods for the isolation, propagation and application of bacteriophages against phytopathogens affecting trees/plants that are of commercial interest for their fruit, flowers etc., for the prevention, treatment or reduction of signs, in particular, for Xanthomonas a. pv juglandis in walnuts.

COMPOSITION COMPRISING BACTERIOPHAGES FOR REDUCING, ELIMINATING AND/OR PREVENTING SALMONELLA ENTERITIDIS, SALMONELLA TYPHIMURIUM AND SALMONELLA PARATYPHI B

The present invention relates to a new cocktail of bacteriophages with specific lytic activity against Salmonella enteritidis, Salmonella typhimurium and Salmonella paratyphi B., for reducing, eliminating and/or preventing them in farm animals and animals from the poultry sector, such as poultry, hens and breeding hens, in addition to eggs. It may be administered as an additive in the feed, in water or by spray. Moreover, the cocktail may be used as a disinfectant in work areas of farms and abattoirs, and in processed foods, without affecting the organoleptic properties of the product.

Composition of matter: engineering of Escherichia coli phage K1E

The present disclosure provides compositions including recombinant K1E bacteriophages, methods for making the same, and uses thereof. The recombinant K1E bacteriophages disclosed herein are useful for the identification and/or antibiotic susceptibility profiling of specific bacterial strains/species present in a sample.

DEVICE AND METHODS FOR ACNE THERAPEUTICS: ANTIBACTERIAL BACTERIOPHAGES AND ENGINEERED LYSINS

Recombinantly-modified Cutibacterium acnes-specific bacteriophage, and recombinantly modified bacteriophage-derived endolysin enzyme are provided. Such compositions, alone or in combination with other antimicrobial agents or immunomodulators, may be used in pharmaceutical compositions, particularly pharmaceutical compositions to treat acne, promote wound healing, inhibit the growth of biofilms and to decrease the likelihood of, prevent or treat surgical related infections. The present invention is particularly directed to such formulations that are compounded for topical administration to a subject or used for application to medical devices. In particular, such pharmaceutical compositions may be compounded for topical administration to a subject, or compounded for application to a medical device.

Protease activity profiling via programmable phage display of comprehensive proteome-scale peptide libraries

The present invention relates to the field of proteases. More specifically, the present invention provides compositions and methods useful for profiling protease activity using phage display. In one embodiment, a display vector useful for profiling protease activity comprises a nucleic acid sequence encoding (a) a peptide to be displayed on the surface of the vector; (b) a first affinity tag C-terminal to the peptide; and (c) a second affinity tag N-terminal to the peptide. The display vector can comprise a virus, bacteriophage, yeast, bacteria, retrovirus, ribosome or mRNA. In particular embodiments, the peptide comprises a human peptidome library peptide.

BACTERIOPHAGES WITH IMPROVED ANTIMICROBIAL ACTIVITY

Provided herein are bacteriophages engineered to express an exopolysaccharide (EPS) depolymerase for treating bacterial infections. In some embodiments, the EPS depolymerase comprises alginate lyase. Also envisioned within the scope of the invention are compositions comprising one or more of the bacteriophages, methods for treating bacterial infections, and kits comprising the compositions described herein.